reliability of HbA 1c in the presence of this variant is also important. In our population we have diabetic patients who are homozygous for Hbs E and D. In-house in vitro studies on patients who are homozygous for Hb S, E, C, D and G Coushatta show that, although they glycate at a slightly di¡erent rate to HbA, the di¡erence is small (55%) and does not sigini¢cantly alter the quantity of glycohaemoglobin produced.
We have therefore concluded that it is possible to assess the glycaemic control in diabetic patients who are either homozygous or heterozygous for several Hb variants using the HbA 1c value from an immunological method in either an absolute or relative manner.
